Use of Stem Cells for COVID-19 Treatment
Conditions
Keywords
Stem Cells, COVID-19, SARS CoV2, WJ MSCs, Immunomodulation,
Brief summary
The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.
Detailed description
COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other. Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.
Interventions
BIOLOGICALWJ-MSCs
WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs. WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.
Sponsors
Stem Cells Arabia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
None. This is a direct study for the potential effects of WJ-MSCs on COVID-19 outcome.
Intervention model description
Patients positively diagnosed with COVID-19
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.
Exclusion criteria
* Participants in other clinical trials * patients with malignant tumors * pregnant and lactating women * co-infection with other infectious viruses or bacteria * History of several allergies * Patients with history of pulmonary embolism * any liver or kidney diseases * HIV positive patients * Considered by researchers to be not suitable to participate in this clinical trial * Chronic heart failure with ejection fraction less than 30%.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical outcome | 3 weeks | Improvement of clinical symptoms including duration of fever, respiratory destress, pneumonia, cough, sneezing, diarrhea. |
| CT Scan | 3 weeks | Side effects measured by Chest Readiograph |
| RT-PCR results | 3 weeks | Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| RT-PCR results | 8 weeks | Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative |
Countries
Jordan
Contacts
Primary ContactAdeeb M AlZoubi, Ph.D.
Backup ContactAhmad Y AlGhadi, M.Sc.
Outcome results
None listed